Direct access to validated animal study protocols, botanical potency quantification, and specialized method developments aligned with Russian and Eurasian Pharmacopoeia standards.
OEM Animal Study Services & In Vivo Pharmacology for Moscow R&D Hubs
ODM Study & Botanical Potency Evaluation Serving Moscow Natural Pharma
Establishment of HPLC/GC Analysis Methods Aligned with EAEU Pharmacopoeia
ODM Clinical Study Support (Phase I - IV) Bridging In Vivo to Human Trials
Moscow stands at the epicenter of the Eurasian pharmaceutical paradigm shift. Driven by Russia’s Pharma 2030 Strategy, the municipal biopharmaceutical cluster—anchored by Technopolis Moscow (Special Economic Zone sites in Alabushevo, Pechatniki, and Rudnevo), the Skolkovo Innovation Center, and premier biomedical institutes like Sechenov First Moscow State Medical University—is radically re-engineering its preclinical pipelines toward high-integrity, sovereign innovation.
Registration of new chemical entities (NCEs), biosimilars, and standardized botanical medicines across the Eurasian Economic Union requires uncompromising compliance with EAEU Decision No. 78 and Decision No. 81. Preclinical animal studies must mirror OECD Good Laboratory Practice (GLP) to ensure unconditional data acceptance across Russian and Eurasian health authorities.
While Moscow houses elite clinical research universities, domestic animal research vivariums face acute backlogs in high-barrier animal models—such as transgenic rodents, Specific Pathogen-Free (SPF) rabbit colonies, and standardized toxicology studies. Sourcing from our world-class research platforms mitigates years of testing delays.
Russian healthcare has an illustrious history of botanical therapy and adaptogenic science. Moscow biotechs are aggressively modernizing traditional phytomedicine into evidence-based therapeutics. This demands deep in vivo bioequivalence, systemic toxicity profiling, and pharmacokinetic validation before submission to Roszdravnadzor.
Understanding the distinct therapeutic focuses of the Moscow and wider Russian clinical community enables us to deploy precision-tailored animal models that address major regional health burdens with uncompromising scientific validity.
Cardiovascular diseases represent a dominant healthcare challenge in the Russian Federation. We provide validated murine and rodent models for myocardial ischemia-reperfusion injury, Dahl salt-sensitive hypertension, and diet-induced hyperlipidemia/atherosclerosis. Moscow pharmaceutical developers use our animal cohorts to validate novel cardioprotective compounds, peptide vasodilators, and synthetic antithrombotic candidates.
Moscow’s biomedical researchers (including cancer institutes such as the Blokhin National Medical Research Center) require high-fidelity tumor growth kinetics and immune-competent models. We run cell-line derived xenografts (CDX), orthotopic models, and syngeneic murine platforms to quantify checkpoint inhibitor efficacy, tumor microenvironment alteration, and targeted botanical alkaloid oncolytic cytotoxicity.
Russian botanical pharmacology has long studied adaptogens (e.g., Panax ginseng, Rhodiola rosea, Eleutherococcus senticosus). Our animal studies quantify stress resilience, HPA-axis modulation, corticosterone normalization, and neuroprotective activity in Parkinsonian (MPTP/6-OHDA) and Alzheimer's (Aβ1-42 infused) rodent cohorts, bridging traditional pharmacological concepts with rigid modern bioassays.
Before moving to clinical volunteer cohorts in Moscow clinics, chemical and botanical products must undergo stringent toxicology testing. We perform single-dose acute toxicity (LD50 determination), 14/28-day repeated dose oral toxicity, 90-day sub-chronic studies, Ames bacterial reverse mutation tests, and mammalian in vivo micronucleus assays in strict compliance with OECD/EAEU technical standards.
Geopolitical and logistics recalibrations have cemented the Sino-Russian scientific alliance. As Western CRO pipelines have become uncertain, our centralized preclinical hubs in China provide unmatched scale, rapid study initiation, and total cost efficiency.
Our barrier vivariums house millions of pathogen-free rodent, rabbit, and non-rodent models. Moscow sponsors bypass regional animal quarantine bottlenecks, benefiting from instant study cohort allocation and uniform genetic lineages.
High-density operational clusters and integrated bioanalytical chemistry deliver comprehensive in vivo safety and efficacy packages at a fraction of Western European fee structures, conserving capital for Moscow sponsors' Phase I trials.
Unlike isolated animal vivariums, MedGence bridges the complete bench-to-clinic pipeline: botanical active extraction, HPLC fingerprinting, in vitro screening, animal pharmacology, and GMP clinical-batch manufacturing under one roof.
Worldwide preclinical drug development is undergoing rapid technological convergence. While the US FDA and European EMA mandate rigid data authenticity via 21 CFR Part 11 and OECD GLP, the Eurasian Economic Union (EAEU) has fully aligned its regulatory philosophy through Decision No. 78 (Rules for Registration and Expertise of Medicines for Medical Use).
Every animal study protocol we generate is specifically structured to slot directly into Module 4 (Nonclinical Study Reports) of the Common Technical Document (CTD) required by the Russian Ministry of Health (Minzdrav) and the Scientific Centre for Expert Evaluation of Medicinal Products (SCEEMP).
We understand the acute IP sensitivity of Russian innovative drug pipelines. Under strict bilateral Non-Disclosure Agreements (NDAs), all test compound structures, botanical formula ratios, biological raw datasets, and pathological specimens remain exclusively the proprietary property of the sponsor.
To facilitate seamless regulatory review in Moscow without technical distortion, study protocols, raw bioanalytical chromatograms, histopathology slides, and final executive summaries are available with coordinated English and Russian scientific dossiers.
As biomedical science transitions toward automated pathology, multi-omics, and the 3Rs ethical framework (Replacement, Reduction, Refinement), our preclinical roadmaps equip Moscow research institutes with cutting-edge trial design.
High-resolution whole-slide imaging combined with machine learning algorithms for objective tissue lesion scoring, fibrosis quantification, and automated cellular morphology evaluation in rat and mouse organ sections.
Implantable micro-telemetry devices in un-anesthetized animals for 24/7 continuous monitoring of blood pressure, electrocardiogram (ECG), respiratory rate, and core body temperature during safety pharmacology evaluations.
Integrating in vitro 3D human organoids (liver, intestinal, cardiac) with targeted animal models to weed out hepatotoxic or cardio-toxic botanical compounds before initiation of chronic in vivo animal cohorts.
Sub-nanogram quantification of complex botanical multi-component mixtures and metabolites in small plasma volumes, creating precision pharmacokinetic (PK) profiles that accelerate Russian IND filings.
Conducting preclinical studies across borders demands rigorous logistics management, absolute temperature preservation, and seamless customs facilitation. We have engineered a rock-solid protocol for Moscow pharma sponsors.
From proprietary active pharmaceutical ingredients (APIs) shipped to our testing facilities to biospecimen/tissue shipments returned to Moscow laboratories, we manage -80°C dry-ice and liquid nitrogen freight lines that preserve sample integrity through Sheremetyevo (SVO) and Domodedovo (DME) hubs.
We provide complete material declarations, safety data sheets (MSDS), Certificates of Analysis (COA), and biological import/export compliance paperwork. We coordinate with Russian regulatory brokerages to avoid delays at customs entry points.
Our scientific liaison team operates across aligned time zones (MSK / UTC+3), ensuring rapid responses, weekly video milestone conferences, live study protocol adjustments, and immediate resolution of technical questions.
Comprehensive insights into GLP validation, animal welfare oversight, regulatory data acceptance in Russia, and cross-border study mechanics.
Deploying complete laboratory capabilities to advance your biological candidates, phytopharmaceuticals, and medical devices from bench-side screening to regulatory registration.
OEM Animal Study & In Vivo Pharmacology Protocols for Moscow Biotech
Botanical Potency & Seasonality Evaluation for Moscow Phytomedicine
Analytical Fingerprint & Chromatography Development (EAEU Compliant)
Clinical Study Management (Phase I-IV) Supporting Russian NDAs
High-Throughput In Vitro Bioassay & Cellular Toxicology Screening
Target Active Molecule Screening from Natural Botanical Libraries
GLP Toxicology, LD50 & Chronic Safety Studies for Moscow Sponsors
Custom Botanical Ingredient Extraction & Pilot Scale Supply for Moscow
Connect with our senior study directors today. Whether you require acute toxicology testing, in vivo disease pharmacology, or botanical bioequivalence evaluation, we deliver audit-proof dossiers engineered for Russian regulatory approval.
